Icatibant Aguettant

Icatibant, the active ingredient in Icatibant Aguettant, is a Bradykinin B2 receptor antagonist presented as a subcutaneous formulation for injection use. It is indicated for the treatment of hereditary angioedema attacks in patients with confirmed disease.

GNH USA supplies Icatibant Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is a targeted therapy for hereditary angioedema, acting on the bradykinin pathway to control swelling.

- Hereditary angioedema type I: rapid relief of swelling episodes. - Hereditary angioedema type II: rapid relief of swelling episodes. - Acute hereditary angioedema attacks: reduces duration and severity of attacks.

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Erythema: localized redness around the injection area. - Nausea: occasional feeling of queasiness. - Headache: transient mild headache.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or anaphylaxis. - Severe hypotension: sudden drop in blood pressure. - Laryngeal edema: swelling of the throat that may affect breathing. - Angioedema at non‑target sites: unexpected swelling elsewhere in the body.

Before using Icatibant, consider the following safety measures.

- Pregnancy: consult a healthcare professional before use. - Breastfeeding: assess risk versus benefit with a physician. - Renal impairment: monitor renal function and adjust therapy as needed. - Concomitant ACE inhibitors: use caution due to potential interaction. - Known hypersensitivity: do not use in patients with documented allergy to icatibant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that affect the bradykinin system or cardiovascular function.

Major Interactions (Avoid): - ACE inhibitors: may diminish icatibant efficacy and increase bradykinin levels. - Neprilysin inhibitors: can raise bradykinin concentrations, reducing therapeutic benefit. - Estrogen‑containing oral contraceptives: may increase frequency of HAE attacks.

Moderate Interactions (Monitor Closely): - Angiotensin receptor blockers: monitor for reduced response to icatibant. - Diuretics: observe blood pressure and fluid balance. - Other B2 receptor antagonists: potential additive effects on bradykinin pathways.